Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199783 | 0.85 | NPSR1 (0.44) | NPSR1ALOX15HCAR2ALDH1A1MAPT | |
| SCHEMBL4199779 | 0.85 | NPSR1 (0.44) | NPSR1ALOX15HCAR2ALDH1A1MAPT | |
| SCHEMBL4199787 | 0.85 | NPSR1 (0.44) | NPSR1ALOX15HCAR2ALDH1A1MAPT | |
| SCHEMBL4199790 | 0.85 | NPSR1 (0.44) | NPSR1ALOX15HCAR2ALDH1A1MAPT | |
| SCHEMBL4209647 | 0.82 | NPSR1 (0.42) | NPSR1ALOX15HCAR2ALDH1A1TSHR | |
| SCHEMBL4205642 | 0.82 | NPSR1 (0.42) | NPSR1ALOX15HCAR2ALDH1A1TSHR | |
| SCHEMBL4205647 | 0.82 | NPSR1 (0.42) | NPSR1ALOX15HCAR2ALDH1A1TSHR | |
| SCHEMBL4205643 | 0.82 | NPSR1 (0.42) | NPSR1ALOX15HCAR2ALDH1A1TSHR | |
| SCHEMBL15811726 | 0.81 | NPSR1 (0.44) | NPSR1ALOX15HCAR2ALDH1A1TSHR | |
| SCHEMBL5325150 | 0.81 | NPSR1 (0.41) | NPSR1ALOX15HCAR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546138-B2 | Pyridone derivatives and uses thereof in the treatment of tuberculosis | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| US-9546138-B2 | Pyridone derivatives and uses thereof in the treatment of tuberculosis | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| EP-2931716-B1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | NOVARTIS AG (CH) | 2016-11-02 | — | — | EP | disclosed |
| US-20150291526-A1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | NOVARTIS AG (CH) | 2015-10-15 | — | — | US | disclosed |
| US-20150291526-A1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | NOVARTIS AG (CH) | 2015-10-15 | — | — | US | disclosed |
| US-7396936-B1 | Modulators of calcitonin and amylin receptor activity | KEMIA, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396936-B1 | Modulators of calcitonin and amylin receptor activity | KEMIA, INC. (US) | 2008-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291526-A1 | PYRIDONE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF TUBERCULOSIS | COASY, PLPBP, ACSS2 | NPSR1 2294/4885ALOX15 439/4885HCAR2 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.